AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral pan-KRAS inhibitor KST-6051 in solid tumors.

Original title: “AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B”

Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.

Original title: “FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results”

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

Original title: “Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’”

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.

Original title: “Coultreon banks $125M to support testing of former Galapagos immune drug”

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.

Original title: “Novartis’ sales dip as generics pressure intensifies, radioequivalents loom”

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.

Original title: “Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.”

Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.

Original title: “Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up”

The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.

Original title: “Garijo starts as Sanofi CEO with window to ease reliance on Dupixent”

Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and in vivo CAR T company Kelonia Therapeutics.

Original title: “Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax”

Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics (health data science concentration), prepares you with a strong foundation in biostatistical and data science methods combined with rigorous training in applied skills to make critical data-driven decisions and meet the growing demand for leaders in this industry – on your schedule

Original title: “Turn health data into impact: Browns University's online master in biostatistics & health data science”